Mizuho raised the firm’s price target on Axsome Therapeutics (AXSM) to $195 from $137 and keeps an Outperform rating on the shares following the patent settlement with Teva (TEVA). The firm removed the impact of a previously anticipated 2034 launch of a generic version of Auvelity within its 2025 to 2037 forecast period. With no other generic challengers expected, this is a “major positive” for Axsome, the analyst tells investors in a research note. Mizuho says the company’s attractiveness to potential strategics “could now meaningfully increase,” while the news should help remove a long-standing overhang on the shares.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- TD ups Axsome target, sees takeout speculation on patent settlement
- Axsome Therapeutics initiated with a Buy at Deutsche Bank
- Axsome Therapeutics price target raised to $150 from $110 at Leerink
- Analyst Upgrades Axsome to Buy Amid Key Settlement with Teva and Raised Price Target
- Shares in Biopharma Firm Axsome Surge Over 20% After Settling Teva Patent Dispute